1 – 15 of 15
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Primary central nervous system lymphomas : EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
(
- Contribution to journal › Article
-
Mark
Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma
(
- Contribution to journal › Article
-
Mark
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE) : a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network
(
- Contribution to journal › Article
- 2023
-
Mark
Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe : The SCHOLAR-2 retrospective chart review study
(
- Contribution to journal › Article
- 2022
-
Mark
Tackling Mantle Cell Lymphoma in Europe
(
- Contribution to journal › Article
-
Mark
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma
(
- Contribution to journal › Article
- 2021
-
Mark
EHA/ESMO Clinical Practice Guidelines for the Management of Malignant Lymphoma : Recommendations for the Second Phase of the COVID-19 Pandemic
(
- Contribution to journal › Scientific review
-
Mark
American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma
(
- Contribution to journal › Article
-
Mark
ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma
(
- Contribution to journal › Article
- 2018
-
Mark
Treatment for patients with relapsed/refractory mantle cell lymphoma : European-based recommendations
(
- Contribution to journal › Article
- 2017
-
Mark
Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus
(
- Contribution to journal › Article
- 2016
-
Mark
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
(
- Contribution to journal › Article
-
Mark
The european hematology association roadmap for european hematology research : A consensus document
(
- Contribution to journal › Article
- 2015
-
Mark
Update on the molecular pathogenesis and targeted approaches of mantle cell lymphoma: summary of the 12th annual conference of the European Mantle Cell Lymphoma Network
(
- Contribution to journal › Scientific review
- 2010
-
Mark
Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma
(
- Contribution to journal › Article